Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2022-11-30
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What is the impact of care bundle in AKI progression?
* Some improvement of care bundle adhesion rate through an electronic alert can be achieved?
Participants will be adults and critical patients with AKI. During observational study the incidence and progression of AKI will be measured, as well spontaneous care bundle adhesion by medical team. In the interventional study, the progression rate of AKI influenced by care bundle will be measured, as well the adhesion of care bundle through an electronic alert inserted in the patient's daily medical record.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Care Bundle in Acute Kidney Injury
NCT02534584
Nephroprotection in Severe Trauma Patients With Kidney Stress
NCT06834633
The Effect of Automated Electronic Alert for Acute Kidney Injury on the Outcomes of Hospitalized Patients
NCT03736304
Electronic Warning Systems in Diagnosis and Treatment of AKI
NCT03119480
Risk Factors And Outcomes Of Hospital Acquired AKI
NCT06051708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During observational and interventional studies clinical and laboratorial information from electronic medical records will be registered. AKI diagnosis and classification will be based on serum creatinine levels according to kidney disease improving global outcomes (KDIGO) criteria.
The observational study will be carried out to measure the incidence of AKI KDIGO 1 and its progression rate, in order to estimate sample size for the interventional study. Researchers assumed a 10% to 20% reduction in the progression of AKI KDIGO 1 to more advanced stages after the implementation of the care bundle. In the interventional study, the care bundle will be included in the medical records of each individual who develops AKI KDIGO 1. Patients included in this study will be followed by 7 days from inclusion. Adhesion rate to the care bundle will be measured between observational and interventional studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Insertion of care bundle in the electronic medical record of patients who develop AKI.
Care bundle for AKI
To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Care bundle for AKI
To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients without AKI or with AKI KDIGO 1 at the time of admission
Exclusion Criteria
* Patients with kidney transplant
* Patients with AKI KDIGO 2, 3 or on dialysis at the time of inclusion in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Estadual Paulista Júlio de Mesquita Filho
OTHER
University of Campinas, Brazil
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lygia Lussim
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lygia Lussim
Role: PRINCIPAL_INVESTIGATOR
University of Campinas, Brazil
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
61447422.1.1001.5404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.